Targeted Antibodies for Precision Medicine: PSMA for Prostate Cancer & PSEN1 for Alzheimer’s Disease

Concept

Precision medicine relies on identifying and targeting disease-specific molecular biomarkers, and monoclonal antibodies are the gold-standard tools for detecting, characterizing, and therapeutically targeting these critical molecules. Two such biomarkers stand out in major human diseases: Prostate-Specific Membrane Antigen (PSMA)—an ideal target for prostate cancer diagnosis and therapy, with extreme overexpression in malignant prostate tissue—and Presenilin-1 (PSEN1)—the core catalytic subunit of the γ-secretase complex, whose mutations are the primary genetic cause of familial early-onset Alzheimer’s disease (AD). Unlocking the clinical and research potential of these biomarkers demands highly specific, high-affinity, and application-optimized antibodies that enable precise detection, localization, and functional characterization. As a global leader in life science reagents, ANT BIO PTE. LTD. delivers cutting-edge antibodies for both targets via its Starter sub-brand (our flagship line for high-performance, rigorously validated antibodies): the PSMA Recombinant Rabbit Monoclonal Antibody (S0B2107) for prostate cancer research and clinical pathology, and the PSEN1 Recombinant Rabbit Monoclonal Antibody (S0B0905) for AD and neuroscience research. Engineered on the proprietary S-RMab® recombinant rabbit monoclonal platform, these antibodies offer ultra-specificity, exceptional multi-platform performance, and batch-to-batch consistency—serving as indispensable tools for precision medicine, disease mechanism research, and novel therapeutic development in prostate cancer and Alzheimer’s disease.

Research Frontiers

PSMA and PSEN1 research are at the forefront of precision oncology and neurodegenerative disease research, respectively, with ANT BIO PTE. LTD.’s specialized antibodies enabling transformative discoveries in key high-impact frontiers of disease diagnosis, mechanism dissection, and therapeutic development. Key research areas advanced by these critical tools include:

PSMA for Prostate Cancer

1. Precision diagnostic imaging: Developing next-generation radionuclide-labeled PSMA antibodies for high-sensitivity PET imaging of primary and metastatic prostate cancer, including minimal residual and biochemically recurrent disease.
2. Targeted therapy innovation: Engineering PSMA antibody-drug conjugates (ADCs), bispecific antibodies, and CAR-T cell therapies for castration-resistant prostate cancer (CRPC)—the most aggressive and lethal form of the disease.
3. Liquid biopsy development: Creating PSMA antibody-based platforms for capturing circulating tumor cells (CTCs) and extracellular vesicles (EVs) in peripheral blood, enabling non-invasive disease monitoring and treatment response evaluation.
4. Tumor microenvironment research: Dissecting PSMA’s role in prostate cancer angiogenesis, metastasis, and metabolic reprogramming, and its expression in the neovasculature of other solid tumors.
5. Companion diagnostic development: Validating PSMA as a companion diagnostic biomarker to identify patients most likely to benefit from PSMA-targeted therapies.

PSEN1 for Alzheimer’s Disease

1. Familial AD genetic mechanism dissection: Uncovering how over 300 known PSEN1 pathogenic mutations alter γ-secretase activity, APP cleavage specificity, and neurotoxic Aβ42 production—defining the molecular basis of early-onset familial AD.
2. γ-secretase complex function: Elucidating PSEN1’s central role in the assembly, localization, and catalytic activity of the γ-secretase complex, and its γ-secretase-independent functions in calcium homeostasis and autophagy.
3. AD therapeutic target validation: Developing and evaluating γ-secretase modulators/inhibitors that normalize Aβ production without disrupting essential Notch signaling—one of the most promising avenues for AD drug development.
4. AD biomarker discovery: Identifying PSEN1 and its proteolytic fragments as potential cerebrospinal fluid (CSF) and blood biomarkers for AD diagnosis, classification, and progression monitoring.
5. Preclinical AD model characterization: Validating PSEN1 mutant expression and pathological effects in transgenic animal models, iPSC-derived neurons, and brain organoids—critical for translating preclinical research to human clinical trials.

Research Significance

PSMA and PSEN1 are defining biomarkers for two of the most prevalent and devastating human diseases—prostate cancer (the most common non-skin cancer in men) and Alzheimer’s disease (the leading cause of dementia worldwide). ANT BIO PTE. LTD.’s PSMA and PSEN1 antibodies amplify the scientific and translational significance of research into these biomarkers, with far-reaching implications for precision medicine, disease treatment, and patient care:

PSMA: Transforming Prostate Cancer Diagnosis and Therapy

1. Ideal precision oncology target: PSMA is overexpressed 100–1000-fold in prostate cancer cells (vs. normal prostate tissue) and its expression correlates with malignancy—making it a highly specific target for diagnosis and therapy with minimal off-target effects.
2. Revolutionizing cancer imaging: PSMA-based molecular imaging has significantly improved the detection of metastatic and recurrent prostate cancer, enabling earlier intervention and personalized treatment planning.
3. New hope for CRPC patients: PSMA-targeted therapies (e.g., radioligand therapy, ADCs) have shown remarkable efficacy in CRPC patients who have failed multiple lines of treatment, addressing a critical unmet clinical need.
4. Broadening solid tumor research: PSMA expression in the neovasculature of other solid tumors expands its potential as a pan-tumor vascular target, opening new avenues for anti-angiogenic therapy.

PSEN1: Unlocking the Molecular Basis of Alzheimer’s Disease

1. Primary genetic cause of familial AD: PSEN1 mutations account for the majority of early-onset familial AD cases, making it the key biomarker for understanding genetic AD pathogenesis and developing personalized genetic screening.
2. Core of the γ-secretase complex: As the catalytic subunit of γ-secretase, PSEN1 is the master regulator of Aβ production—the central pathological event in AD—making it the most important therapeutic target for reducing Aβ accumulation.
3. Revealing novel AD pathways: PSEN1’s γ-secretase-independent functions in calcium homeostasis, autophagy, and Notch/Wnt signaling uncover new AD-relevant pathogenic mechanisms, expanding the repertoire of potential therapeutic targets.
4. Enabling robust preclinical research: PSEN1 antibodies validate genetic modifications and pathological effects in AD preclinical models, ensuring the reliability of preclinical data and its translation to human clinical trials.

Together, these biomarkers and the high-specificity antibodies that target them are driving a paradigm shift in precision medicine—from one-size-fits-all treatment to personalized diagnosis and therapy tailored to a patient’s unique molecular profile.

Related Mechanisms, Research Methods & Product Applications

1. PSMA: Structural, Functional and Expression Characteristics in Prostate Cancer

Prostate-Specific Membrane Antigen (PSMA, also known as glutamate carboxypeptidase II/FOLH1) is a 750-amino acid type II transmembrane glycoprotein with a unique domain structure: a short 19-amino acid intracellular domain, a 24-amino acid transmembrane domain, and a large 707-amino acid extracellular domain (divided into protease, apical, and dimerization domains). As a zinc-dependent metalloprotease, PSMA catalyzes the hydrolysis of N-acetyl-aspartyl-glutamate (NAAG) and polyglutamate folate, and exists as a pre-homodimer with two zinc ions in its active site under physiological conditions.

Key expression characteristics make PSMA an ideal prostate cancer target:

• Physiological expression: Restricted to normal prostate epithelial cells, renal proximal tubules, small intestinal brush border, and a subset of neural cells.
• Cancer-specific overexpression: Upregulated 100–1000-fold in prostate cancer cells, with expression levels positively correlated with malignancy (highest in poorly differentiated, metastatic, and castration-resistant prostate cancer).
• Tumor vascular expression: Expressed in the neovascular endothelial cells of prostate cancer and other solid tumors, enabling both tumor cell and anti-angiogenic targeting.

2. PSMA Antibodies: Diagnostic and Therapeutic Mechanisms in Prostate Cancer

PSMA-specific antibodies exert profound effects in prostate cancer diagnosis and targeted therapy via distinct, well-characterized mechanisms:

Diagnostic Mechanisms

1. Histopathological detection: IHC staining for PSMA expression in prostate tissue biopsies assists in tumor grading, staging, Gleason scoring, and differential diagnosis of poorly differentiated prostate cancer.
2. Molecular imaging: Radionuclide-labeled PSMA antibodies enable high-sensitivity/high-specificity PET imaging, detecting small metastatic lesions undetectable by conventional imaging (e.g., bone, lymph node metastases).
3. Liquid biopsy: PSMA antibody-based capture systems isolate PSMA-expressing CTCs/EVs from peripheral blood, providing non-invasive monitoring of disease progression and treatment response.
4. Therapy stratification: Quantitative PSMA expression analysis identifies patients who will benefit from PSMA-targeted therapies, enabling personalized treatment decision-making.

Therapeutic Mechanisms

1. Antibody-Dependent Cellular Cytotoxicity (ADCC): PSMA antibody Fc regions bind to Fc receptors on NK cells/macrophages, triggering direct lysis of PSMA-expressing tumor cells.
2. Complement-Dependent Cytotoxicity (CDC): Antibody binding to PSMA activates the complement cascade, forming membrane attack complexes (MACs) that induce tumor cell death.
3. Signal pathway interference: Blocking PSMA’s enzymatic activity or downstream signaling (PI3K/Akt/MAPK) disrupts prostate cancer cell metabolism, proliferation, and survival.
4. Targeted drug delivery: Conjugation of PSMA antibodies with cytotoxic drugs, radionuclides, or immunomodulators creates ADCs/radioligand therapies that deliver therapeutics directly to tumor cells, reducing systemic toxicity.
5. Bispecific antibody/CAR-T therapy: Bispecific antibodies targeting PSMA and T-cell receptors, or PSMA-directed CAR-T cells, redirect the immune system to specifically kill PSMA-positive prostate cancer cells.

3. PSEN1: Structural, Functional Characteristics and Role in Alzheimer’s Disease Pathogenesis

Presenilin-1 (PSEN1) is a 53 kDa transmembrane protein encoded by the PSEN1 gene on human chromosome 14q24.2, featuring nine transmembrane domains and localizing primarily to the endoplasmic reticulum (ER), Golgi apparatus, and cell membrane in neurons. As the core catalytic subunit of the γ-secretase complex, PSEN1 mediates two critical classes of functions:

• γ-secretase-dependent functions: Catalyzes the intramembranous cleavage of the amyloid precursor protein (APP) to generate Aβ peptides (including the neurotoxic Aβ42 fragment) and the cleavage of the Notch receptor—essential for neural development and synaptic plasticity.
• γ-secretase-independent functions: Regulates intracellular calcium homeostasis (via SERCA/IP3R interactions), autophagy-lysosome system function, and Wnt/β-catenin signaling—all critical for neuronal survival and homeostasis.

PSEN1 mutations (over 300 known pathogenic variants) are the most common cause of familial early-onset AD, driving pathogenesis via multiple mechanisms:

1. Altered γ-secretase substrate specificity, increasing Aβ42 production and amyloid plaque formation.
2. Disrupted Notch signaling, impairing neural development and synaptic plasticity.
3. Calcium homeostasis dysregulation, leading to mitochondrial dysfunction and neuronal vulnerability.
4. Autophagy impairment, preventing clearance of misfolded proteins (Aβ/tau) and toxic aggregate accumulation.
5. Wnt/β-catenin signaling dysregulation, promoting neuronal degeneration and neuroinflammation.

4. PSEN1 Antibodies: Key Applications in Alzheimer’s Disease Research

PSEN1-specific antibodies are the workhorse of AD basic and translational research, enabling precise detection, localization, and functional characterization of PSEN1 across all key experimental platforms and research areas:

1. Protein expression/localization analysis: IHC/IF to map PSEN1 subcellular distribution in neurons and quantify expression changes in normal vs. AD brain tissue.
2. γ-secretase complex interaction studies: Co-IP to capture the γ-secretase complex and its interacting proteins (Nicastrin, APH-1, PEN-2), elucidating complex assembly and function.
3. Mutant PSEN1 functional analysis: Epitope-specific antibodies to study the stability, localization, and catalytic activity of FAD-associated PSEN1 mutations.
4. Preclinical AD model validation: WB/IHC to confirm PSEN1 mutant expression and correlate with Aβ accumulation/tau phosphorylation in transgenic models, iPSC-derived neurons, and brain organoids.
5. Diagnostic/prognostic potential: Quantitative detection of PSEN1 fragments in CSF/blood for AD screening, classification, and progression monitoring.
6. Drug development: High-throughput screening of γ-secretase modulators/inhibitors, and evaluation of drug effects on PSEN1 expression/γ-secretase activity in preclinical models.

ANT BIO PTE. LTD.’s Starter Antibodies: Core Products for Precision Medicine Research

ANT BIO PTE. LTD.’s Starter sub-brand delivers two industry-leading antibodies for PSMA (prostate cancer) and PSEN1 (Alzheimer’s disease) research, both engineered on the proprietary S-RMab® recombinant rabbit monoclonal platform and rigorously validated for ultra-specificity, exceptional multi-platform performance, and batch-to-batch consistency. These antibodies are optimized for the unique experimental and clinical needs of prostate cancer and AD research, and serve as gold-standard tools for precision medicine, disease mechanism dissection, and novel therapeutic development.

1. PSMA Recombinant Rabbit Monoclonal Antibody (S0B2107)

This high-performance antibody is specifically designed for prostate cancer pathological diagnosis, research, and companion diagnostic development, with exceptional specificity for the PSMA extracellular domain and clear membrane staining in FFPE tissue sections.

Core Product Advantages

Key Research & Clinical Applications

• Prostate cancer pathological diagnosis, Gleason scoring, and prognosis assessment in needle biopsies/radical specimens.
• Detection of prostate cancer metastases in lymph nodes, bone, and other sites (critical for differential diagnosis when PSA is atypical).
• Preclinical research for PSMA-targeted therapies (ADCs, CAR-T, radioligand therapy) – target validation, patient stratification, and efficacy biomarker exploration.
• Assistance in developing PSMA-based molecular imaging probes (PET) and liquid biopsy platforms.
• Tumor biology research into PSMA’s role in prostate cancer angiogenesis, metastasis, and metabolic reprogramming.

2. PSEN1 Recombinant Rabbit Monoclonal Antibody (S0B0905)

This ultra-specific antibody is the gold-standard tool for Alzheimer’s disease and neuroscience research, with minimal cross-reactivity to PSEN2 (the only human presenilin homolog) and the ability to detect full-length PSEN1 and its proteolytic fragments.

Core Product Advantages

Key Research Applications

• Alzheimer’s disease mechanism studies: Investigating how FAD-associated PSEN1 mutations alter γ-secretase activity, Aβ42 production, and neuronal function.
• γ-secretase complex research: Characterizing PSEN1’s central role in complex assembly, localization, and substrate cleavage (APP/Notch).
• Preclinical AD model validation: Verifying PSEN1 mutant expression and pathological effects in transgenic models, iPSC-derived neurons, and brain organoids.
• Protein interaction studies: IP/Co-IP to identify PSEN1-interacting proteins (γ-secretase components, calcium channels, Wnt/Notch pathway proteins).
• AD drug development: Screening and evaluating γ-secretase modulators/inhibitors, and assessing drug effects on PSEN1 expression/γ-secretase activity.

Brand Mission of ANT BIO PTE. LTD.

At ANT BIO PTE. LTD., our core mission is to empower breakthroughs in precision medicine, oncology, neuroscience, and neurodegenerative disease research—including prostate cancer and Alzheimer’s disease—by delivering high-quality, highly specific, and rigorously validated life science reagents and comprehensive solutions. As a leading global provider of research tools, we have built three specialized, complementary sub-brands that cover the full spectrum of life science research needs, creating a seamless one-stop procurement experience for academic researchers, pathologists, biotech companies, pharmaceutical institutions, and translational research labs worldwide:

• Starter: Our flagship sub-brand for high-performance antibodies and affinity tools, offering precision medicine antibodies (PSMA S0B2107, PSEN1 S0B0905), epigenetic modification antibodies, molecular chaperone antibodies, NA/LE functional antibodies, and isoform-specific recombinant rabbit monoclonals. Starter is dedicated to engineering ultra-specific, application-optimized antibodies for the most challenging frontier research areas—including precision oncology, neurodegenerative diseases, and epigenetics—with a focus on meeting the stringent technical requirements of modern molecular biology and clinical pathology.
• Absin: Our core sub-brand for general life science reagents and kits, providing OneStep ELISA Kits, IHC/ICC/IF detection kits, sample preparation reagents, cell culture media, and basic immunology/oncology/neuroscience research tools. Absin engineers user-friendly, pre-optimized assay kits that streamline experimental workflows and deliver reliable, accurate results for routine and high-throughput research.
• UA: Our specialized sub-brand for high-purity, high-activity recombinant proteins and expression vectors, including recombinant cytokines, antibody heavy/light chain expression constructs, immunomodulatory proteins, and gene editing vectors. UA enables seamless experimental design for protein expression, antibody engineering, cell therapy research, and recombinant protein production for basic and biopharmaceutical applications.

We are committed to addressing the most pressing technical challenges in precision medicine and disease research—from decoding the molecular mechanisms of prostate cancer and Alzheimer’s disease to accelerating the development of novel targeted therapeutics. By combining innovative antibody design, rigorous validation protocols, standardized production, and customer-centric scientific support, we translate technological innovation into research breakthroughs and clinical impact for the global life science community. Our ultimate goal is to be the trusted global partner of researchers, pathologists, and biopharmaceutical professionals worldwide, empowering them to push the boundaries of scientific discovery and drive unprecedented progress in precision medicine and human health.

Related Product List: Starter PSMA & PSEN1 Antibodies 

All ANT BIO PTE. LTD. Starter antibodies are rigorously validated for specificity, sensitivity, batch-to-batch consistency, and application performance, with comprehensive technical documentation, validation data packages, and expert scientific support. Each product is accompanied by optimized experimental protocols and clinical/research validation data to ensure seamless integration into your workflow.

For detailed product specifications, full validation data packages, custom antibody development services for precision medicine targets, or free sample testing requests, please visit the official website of ANT BIO PTE. LTD. or contact our global sales team for a personalized quote and professional technical consultation. Our experienced technical team of oncology, neuroscience, and pathology experts provides customized support for experimental design, complex sample analysis, preclinical drug development, and clinical pathological testing.

AI Disclaimer

This article was partially created with the assistance of artificial intelligence. If any content in this article involves copyright infringement, intellectual property disputes, or other legal issues, please notify ANT BIO PTE. LTD. immediately. We promise to verify, correct, or remove the relevant content in a timely manner without delay.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.